# US 11,078,252 B2 · T-cell receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,078,252 B2
- Document ID: US11078252B2
- Status: Granted
- Kind: B2
- Application number: 17/153,329
- Filed: 2021-01-20
- Published: 2021-05-20
- Granted: 2021-08-03
- Earliest claimed: 2017-10-26
- Assignees: University College Cardiff Consultants Limited
- Applicants: University College Cardiff Consultants Ltd.
- Inventors: Andrew Sewell; Garry Dolton
- Web page: https://patentgrep.com/patent/US11078252B2

## CPC

- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/42: Cancer antigens
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or bispecific comprising said TCR, said cell, said clone or said vector; use of said TCR or said cell or said clone or said vector or said pharmaceutical composition or bispecific to treat cancer; and a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition or bispecific comprising said TCR.

## Claims

### Claim 1

A vector encoding a T-cell receptor (TCR) that comprises
a. an α chain that comprises CDR1α, CDR2α, and CDR3α amino acid sequences that are at least 88% identical to the amino acid sequences of SEQ ID Nos: 3, 4, and 1, respectively; and
b. a β chain that comprises CDR1β, CDR2β, and CDR3β amino acid sequences that are at least 88% identical to the amino acid sequences of SEQ ID Nos: 5, 6, and 2, respectively.

### Claim 2 (depends on 1)

The vector of claim 1, wherein
a. CDR1α comprises the amino acid sequence of SEQ ID NO: 3, CDR2α comprises the amino acid sequence of SEQ ID NO: 4, and CDR3α comprises the amino acid sequence of SEQ ID NO: 1; and
b. CDR1β comprises the amino acid sequence of SEQ ID NO: 5, CDR2β comprises the amino acid sequence of SEQ ID NO: 6, and CDR3β comprises the amino acid sequence of SEQ ID NO: 2.

### Claim 3 (depends on 1)

The vector of claim 1, wherein the α chain comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 7.

### Claim 4 (depends on 1)

The vector of claim 1, wherein the α chain comprises the amino acid sequence of SEQ ID NO: 7.

### Claim 5 (depends on 1)

The vector of claim 1, wherein the β chain comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 8.

### Claim 6 (depends on 1)

The vector of claim 1, wherein the β chain comprises the amino acid sequence of SEQ ID NO: 8.

### Claim 7 (depends on 1)

The vector of claim 1, wherein the α chain comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 7; and the β chain comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 8.

### Claim 8 (depends on 1)

The vector of claim 1, wherein the α chain comprises the amino acid sequence of SEQ ID NO: 7; and the β chain comprises the amino acid sequence of SEQ ID NO: 8.

### Claim 9 (depends on 1)

The vector of claim 1, wherein the vector is a lentiviral vector.

### Claim 10 (depends on 1)

The vector of claim 1, wherein the TCR is a chimeric TCR.

### Claim 11 (depends on 1)

The vector of claim 1, wherein the TCR is MR1-restricted.

### Claim 12 (depends on 1)

The vector of claim 1, wherein the TCR is not expressed by mucosal-associated invariant T-cells (MAIT cells).

### Claim 13 (depends on 1)

A T-cell comprising the vector of claim 1.

### Claim 14 (depends on 2)

A T-cell comprising the vector of claim 2.

### Claim 15 (depends on 3)

A T-cell comprising the vector of claim 3.

### Claim 16 (depends on 4)

A T-cell comprising the vector of claim 4.

### Claim 17 (depends on 5)

A T-cell comprising the vector of claim 5.

### Claim 18 (depends on 6)

A T-cell comprising the vector of claim 6.

### Claim 19 (depends on 7)

A T-cell comprising the vector of claim 7.

### Claim 20 (depends on 8)

A T-cell comprising the vector of claim 8.

### Claim 21 (depends on 9)

A T-cell comprising the vector of claim 9.

### Claim 22 (depends on 10)

A T-cell comprising the vector of claim 10.

### Claim 23 (depends on 1)

A pharmaceutical composition comprising the vector of claim 1.

### Claim 24 (depends on 13)

A pharmaceutical composition comprising the T-cell of claim 13.

### Claim 25 (depends on 1)

A method of treating cancer in an individual in need thereof, comprising administering to the individual the vector of claim 1.

### Claim 26 (depends on 25)

The method of claim 25, wherein the cancer is selected from the group consisting of colorectal cancer, lung cancer, kidney cancer, prostate cancer, cervical cancer, skin cancer, bone cancer, breast cancer, ovarian cancer, and blood cancer.

### Claim 27 (depends on 25)

The method of claim 25, wherein the vector is administered in combination with an anti-tumor agent.

### Claim 28 (depends on 13)

A method of treating cancer in an individual in need thereof, comprising administering to the individual the T-cell of claim 13.

### Claim 29 (depends on 28)

The method of claim 28, wherein the cancer is selected from the group consisting of colorectal cancer, lung cancer, kidney cancer, prostate cancer, cervical cancer, skin cancer, bone cancer, breast cancer, ovarian cancer, and blood cancer.

### Claim 30 (depends on 28)

The method of claim 28, wherein the T-cell is administered in combination with an anti-tumor agent.